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Introduction
There is accumulating clinical evidence suggesting that
it is the degree of injury to an allograft rather than the
degree of foreignness that determines or at least contrib-
utes to its short-term and long-term outcome. Reactive
oxygen species (ROS)-mediated postischemic reperfusion
injury – amongst different kinds of damages – appears to
play a major role in injury-induced regulation of allograft
outcome. Early evidence for this assumption arose from a
prospective clinical trial performed at our institution in
1994 in which we could show that the free radical scaven-
ger superoxide dismutase (SOD) – given during surgery –
leads to a statistically significant reduction in incidences
of acute and chronic rejection events in CsA-treated, kid-
ney-transplanted patients [1]. This clinical observation of
a beneficial effect of SOD on early and late allograft out-
come provided an indirect proof for the assumption that
the generation of superoxide radicals during allograft
reperfusion had a significant impact on allograft sur-
vival.
In view of lack of any experimental and clinical data on
the basis of which we could explain these early clinical
findings, we – in close collaboration with Konrad Mess-
mer and his group – raised a working hypothesis by dis-
cussing the possibility that it is the ROS-mediated reper-
fusion injury that leads to clinical events of alloimmunity
(such as incidences of acute rejection episodes and acute
irreversible rejection) and that, in regard to the underlying
basic mechanism, it is this primary unspecific injury in
terms of a key event that results in an initiation of T-cell
alloactivation via activation of antigen-presenting cells [1,
2]. Subsequently, our hypothetical interpretation of the
clinical findings was extended by discussing the possibili-
ty that the reperfusion injury-associated, ROS-induced
inflammatory milieu of the allograft, associated with an
upregulated cytokine and chemokine response, initiates
activation of sentinel dendritic cells leading to upregula-
tion of (a) MHC-molecules, (b) costimulatory molecules
and (c) adhesion molecules, enabling these cells to interact
with T-cells, and by this inducing an efficient T-cell
alloactivation [3–5].
In regard to recent reports on new exciting findings
from research in the field of innate immunity – which is
precendent to adaptive immunity – it appears now possi-
ble to refine and extend our theory again.
In fact and surprisingly enough, many of those novel
data obtained in the field of innate immunity – now
defined as a host defence system against microbial patho-
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Fig. 1. Three clinical examples of injury-determined allograft out-
come: Group A1/Group A2: SOD trial: 5-year results in SOD-treated
patients (A1) compared to placebo-treated patients (A2). Group B1/
Group B2: 5-year allograft survival in recipients of non-HLA-
matched kidneys from unrelated living donors (B1) compared to his-
torical controls (B2) of post-mortem removed kidney transplants
-
allocated on the basis of a good HLA match via Eurotransplant.
Group C1/Group C2: ‘Senior-Kidney transplant programme’: 5-year
results after allogeneic renal transplantation in elderly recipients of
organs from elderly cadaveric donors, compared to data from the
CTS study.
gens – fit very nicely in our concept that the ROS-
mediated reperfusion injury to allografts creates a milieu
of inflammation that operates as a danger signal and, in
analogy to the infectious-agents-induced inflammation,
may, thus, initiate a state of innate immunity.
In essence, the establishment of an alloimmune re-
sponse to an allograft is primarily due to the inability of
the innate immune system to discriminate between an
inflammatory milieu of host tissue caused by pathogens
on one hand, and an inflammatory state in a transplanted
foreign organ induced by free-radical-mediated reperfu-
sion injury to the allograft on the other hand. The situa-
tion is even more complicated by the fact that in the allo-
grafting setting, the innate immune response of both the
donor and the recipient may become involved by flow-
ing – as a link – in a subsequent adaptive immune
response of the recipient.
By adding the new findings from research in the field
of innate immunity to our reperfusion injury theory, the
whole concept becomes more valid and may provide a
rational approach to new strategies of immunosuppres-
sion and tolerance induction by tackling primarily the
events occurring during ‘innate alloimmunity’ than dur-
ing adaptive alloimmunity – as we are doing now.
In the following chapters, I am going to summarize
some of those new findings from the literature and to try
to put them in a logical and plausible way into the puzzle
posed by our early clinical observation that treatment of a
primary unspecific injury to an allograft results in a
remarkable reduction of subsequent specific alloimmune
events.
The Degree of the ROS-Mediated Injury to an
Allograft Rather than the Degree of Its
Foreignness Contributes to Early and Late Graft
Outcome
Clinical Examples Observed at Our Institution
Apart from the data obtained from our SOD trial [1],
there are two more clinical situations that provide addi-
tional evidence suggesting that it is the degree of ROS-
mediated injury to an renal allograft rather than its degree
of foreignness that determines its short-term and long-
term outcome: the superior results observed (a) in unre-
lated living donor kidney transplantation – a situation in
which the degree of postischemic reperfusion injury is
believed to be minimal; and (b) in kidney transplantation
in elderly recipients of an elderly cadaveric renal allograft
by using a treatment protocol that minimized ROS-
mediated allograft injury.
Therefore, data from these two other clinical trials in
this respect performed at our institution are briefly men-
tioned in this context as well (fig. 1). In the SOD trial
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short-term and long-term results could be improved by
mitigation of the reperfusion injury to the allograft with a
free radical scavenger whereas a multivariate analysis of
the data from this study showed that the degree of MHC/
HLA incompatibilities had no significant influence on
graft survival [6].
In a series of 63 unrelated living donor kidney trans-
plantations in HLA-mismatched recipients we observed a
5-year graft survival rate of 80.8% [7]. When censoring for
patient’s death and technical failure, this rate was 96%
compared to 70% in a series of 1,136 historical controls
who had received well-matched cadaveric renal allografts
allocated on the basis of a good HLA match, however,
associated with long cold ischemia times.
It is well known that transplantation of kidneys from
cadaveric elderly donors into elderly recipients is associ-
ated with poor short-term and long-term results. We sug-
gested that an increased susceptibility of old organs to the
attack of ROS may be responsible for these inferior results
(a theory which could recently be confirmed experimen-
tally [8]). Thus, we tried to keep the ROS-mediated injury
to this category of allograft as small as possible by trying
(1) to avoid application of Ciclosporin, known experi-
mentally to contribute to the generation of reactive oxy-
gen species [9]; (2) accepting kidneys with short cold isch-
emia times only in order to provide no increased postisch-
emic reperfusion injury; and (3) by adding to the immu-
nosuppressive induction regimen (MMF, steroids, ATG)
a course of antioxidative treatment (Vitamin C, Vitamin
E, acetyl cystein). As already published [10], the 3-year
allograft survival rate in this prospective pilot trial was
excellent and superior compared to the corresponding
data from the literature.
Generation of Reactive Oxygen Species during
Postischemic Reperfusion Injury of Human
Cadaveric Renal Allografts
The generation of reactive oxygen species during post-
ischemic reperfusion injury to allografts has been demon-
strated in a large variety of experimental studies and in
clinical studies as well [3]. We were able to measure the
generation of ROS during reperfusion of human cadaver-
ic renal allografts indirectly using malondialdehyde
(MDA) as a marker. In fact, we found an increase of
MDA-TBA adducts in the venous blood taken from the
vein of reperfused renal allografts [11]. Because the
MDA-TBA method is known to be associated with some
methodologic weakness, we tried to apply methods for
direct demonstration of ROS during allograft reperfu-
sion.
Thus recently in collaboration with Messmer and co-
workers, Institute of Surgical Research, we were able to
measure ROS directly during reperfusion of human ca-
daveric renal allografts. Using the EPR spectroscopy tech-
nique, hydroxyl radicals could be measured in the trans-
plant vein appearing already 1 min after reperfusion and
showing a peak in concentration at 5 min and 15 min
(fig. 2a, b).
This very early demonstration of hydroxyl radicals
immediately after onset of reperfusion – indicating the
presence of superoxide and hydrogen peroxide as well –
obviously represent the primary danger signal by inducing
a secondarily-running cascade of events associated with
any kind of oxidative stress (see below).
The Innate Immune System, Toll-Like Receptors
and Their Ligands
Alloimmunity has been interpreted for a long period of
time until recently in terms of a primary adaptive immu-
nity exclusively – the basic paradigm of an adaptive
immune response, clonal selection, defined in terms of a
specific immune response of the recipient against the for-
eign donor MHC-antigens of the allograft.
In contrast, innate immunity has been considered over
a long period of time as a separate entity from the
adaptive immune response and has been regarded to be of
secondary relevance in the hierarchy of immune func-
tions. Recently, however, new insights in mechanisms of
the first line of defence against infection (and thus, against
an infection-associated inflammatory milieu) have been
achieved and have again focussed on the biological phe-
nomenon of innate immunity. In principle, modern as-
sumptions in immunology say that the functioning of the
immune system is based on two distinct recognition sys-
tems: the innate and the adaptive. The innate immunity
interacts with and may lead to the second line of defence
represented by the adaptive immunity. Similarities and
differences in these two types of host response to infection
have been reviewed recently [12, 13].
Innate immunity provides a host defence against infec-
tion and, thus, has to possess the ability to recognize
pathogens, in other words to react with recognition mole-
cules on pathogens = ‘pathogen-associated molecular pat-
tern’ = PAMPs [12, 13].
The question, however, is whether or not – apart from
those PAMPs on microbes – putative endogenous ligands,
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Fig. 2. a Electron paramagnetic resonance
spectroscopy measurement of hydroxyl radi-
cals in the renal allograft vein during post-
ischemic reperfusion. As spin trap DEPM-
PO-OH was used. The typical signals of
1:2.2.1.2.2.1 characteristic for hydroxyl radi-
cals are shown. b Electron paramagnetic res-
onance spectroscopy measurement of hy-
droxyl radicals following reperfusion of hu-
man cadaveric renal allografts: two peaks of
hydroxyl radical generation, at 5 min and at
15 min, were observed (from J. Fertmann et
al., in preparation).
e.g. on damaged host cells, may play a role in this scenar-
io – similar to the Drosophila endogenous ligand ‘Spätzle’
that activates the receptors in cells of the fly in response to
infection [14].
Indeed, recent studies have suggested that chapero-
kines like autologous heat shock protein 60 (hsp60) oper-
ate as such an endogenous ligand and may serve as a dan-
ger signal to the innate immune system. Mouse or human
macrophages, as well human vascular cells and PBMC,
through CD14 signaling and p38 mitogen-activated pro-
tein kinase, were found to elicit a proinflammatory re-
sponse when incubated with recombinant human hsp60
[15–17]. The response included the up-regulation of adhe-
sion molecule expression and the release of inflammatory
mediators such as IL-6 and TNF-·. In addition, human
hsp60 induced gene expression of IL-12 and IL-15.
Moreover and interestingly, microbial hsp60/65 also
induces a proinflammatory response in innate immune
cells [18, 19].
On the other hand, host organisms have developed a
set of non-clonal receptors which can recognize PAMPs
and, therefore, the presence of pathogens. These receptors
have a broad specificity because they can recognize a
number of different ligands, as long as the ligands share a
common molecular pattern = ‘pattern recognition recep-
tors’ = PRRs [12, 13]). These receptors which belong to
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the IL-1 receptor family are known as ‘mammalian Toll-
like receptors’ (TLR) according to the homologous recep-
tor of the Drosophila Toll protein. So far, more than
twelve TLRs have been published, about twenty appear to
exist, TLR 4 and TLR 2 seem to play a major role in the
defence against infection.
Toll-like receptors are strategically expressed on cells
that are the first to encounter pathogens during infection,
such as surface epithelia, and also on all types of effector
cells of the innate immune system, such as dendritic cells
as antigen-presenting cells and macrophages [20, 21]. The
mechanism of Toll-like receptor activation is not quite
clear: as already mentioned above, the question is wheth-
er or not there is a direct interaction between Toll-like
receptors and their putative ligands on microbes, or there
are endogenous ligands on autologous damaged cells that
activate the receptors in response, e.g. to infection.
In regards to the reperfusion injury hypothesis, it is of
interest that a recent study could show that the human
heat shock protein 60 (hsp60) chaperokine operates as an
endogenous TLR4 complex ligand suggesting that it acts
as a danger antigen to the innate immune response [22].
In addition, it could be further shown that activation
by LPS of Toll-like receptors on human immature den-
dritic cells plays an important role in activation and mat-
uration of this category of professional antigen-presenting
cells linking innate immunity to adaptive immunity [23].
Again of interest in the light of the reperfusion injury
hypothesis are recent studies suggesting that Toll-like
receptors share common downstream signalling mole-
cules of the Rel/NF-ÎB pathway. In fact, activation of NF-
ÎB occurs downstream of a number of receptors including
TNF receptors, CD40, the IL-1 receptor and Toll-like
receptors [20, 24, 25]. In addition, there is further evi-
dence suggesting that TLR 4 activates not only NF-ÎB but
also AP-1 and JNK [20, 26] = transcription factors
involved in oxidative stress situations.
In addition, in mammals, engagement of TLR4 and
the IL-1 receptor leads to the sequential activation of
the adapter protein My88, the IL-1 receptor-associ-
ated kinase (IRAK), TNF receptor-associated factor-6
(ZTRAF-6) and eventually the IkB kinase complex [27].
Of further interest in this context are recent data on
signal transduction processes by which injury-induced
cell necroses may lead to activation of genes involved in
inflammation.
Principally, any tissue damage induced by injury or
infection can result in necrosis, a mode of cell death char-
acterized by induction of an inflammatory response. It
has been shown [28] that necrotic cells, but not apoptotic
cells, activate NF-ÎB and induce expression of genes
involved in inflammatory and tissue-repair responses,
including neutrophil-specific chemokine genes KC and
macrophage inflammatory protein-2, in viable fibroblasts
and macrophages. Interestingly, NF-ÎB activation by ne-
crotic cells was dependent on Toll-like receptor 2, the sig-
naling pathway that induces inflammation in response to
microbial agents. These results have identified a novel
mechanism by which cell necrosis, but not apoptosis, can
induce expression of genes involved in inflammation and
tissue repair responses. Furthermore, these results also
demonstrate that the NF-ÎB/Toll-like receptor 2 pathway
can be activated by exogenous microbial agents and
endogenous inflammatory stimuli.
Such observations are of extreme importance for the
assumption that ROS-mediated postischemic reperfusion
injury, which is known to induce an inflammatory milieu,
may act as an endogenous stimulus to activate Toll-like
receptor-bearing cells such as dendritic cells as will be dis-
cussed here.
Possible Scenario of a ‘Double’ Innate Immune
Response (‘Innate Alloimmune Response’)
Initiated by Postischemic Reperfusion Injury to
an Allograft Leading to an Adaptive
Alloimmune Response
Recent findings from research in the field of innate
immunity in terms of a host defence against infection may
let suggest an involvement of the innate immune system
as the first step in the initiation of the adaptive alloim-
mune response of the recipient against an allograft: an
activation of (donor-derived) cells of the donor’s innate
immunity within the allograft inflamed during postisch-
emic reperfusion injury – as well as activation of recipi-
ent-derived cells of the recipient’s innate immune system
entering the allograft – in terms of a transplant recipient’s
defence against the introduced alloantigen of the donor
organ. The underlying principle would be that the innate
immune system – regardless in this situation whether it is
of donor origin or of recipient origin – is not able to differ-
entiate between an inflammation of a tissue mediated by
pathogens and an inflammation of a donor organ me-
diated by reactive oxygen species. The scenario which
may start from initial unspecific reperfusion injury to an
allograft and result in an adaptive alloimmune response is
illustrated in figure 3: The scenario is unique as we are
dealing here with the existence and activation of two
innate immune systems resulting in one adaptive immune
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Fig. 3. Working hypotheses: initiation of adaptive alloimmunity by reperfusion injury to allografts via initiation of
innate (allo)immunity (see text).
response: the innate immunity of the organ donor – repre-
sented by the existence of donor-derived dendritic cells –
leading to the direct pathway of alloactivation by interact-
ing with recipient’s T-cells; and the innate immunity of
the recipient – represented by graft-invading, recipient-
derived dendritic cells – leading to the indirect pathway of
alloactivation.
We may discuss the possibility that the scenario starts
with the generation of reactive oxygen species e.g. in
endothelial cells of donor organ vessel walls which has
been shown to occur within the first minutes after reperfu-
sion of an allograft (fig. 2). This early event is followed by
secondary activation of monocytes and macrophages
which, in turn, are stimulated to generate ROS (well-
known phenomenon of a vicious circle of ROS genera-
tion). As a consequence, the generation of ROS leads to
damage of the donor organ.
The next question is whether or not this injury (oxida-
tive stress) does lead to induction of endogenous ligands
on damaged allogeneic cells that may interact with and
activate Toll-like receptors in response to inflamed tissue
due to this free-radical-mediated injury. Studies on en-
dogenous ligands for Toll-like receptors have only started
to emerge. As mentioned already, a recent study impli-
cated the hsp60 chaperone as an endogenous TLR 4
ligand. In fact, hsp60 is normally sequestered in the cell
interior, but is rapidly translocated to the membrane in
response to any cell stress.
Indeed, numerous experiments in various models have
shown that oxidative stress is able to induce heat shock
proteins [29–34]. The ability of oxidative stress to damage
proteins could account for its ability to induce some of
those stress-induced proteins. In terms of an analogous
interpretation, we would assume that these proteins (acting
and functioning as chaperones) may be induced during oxi-
dative stress in the course of reperfusion of an allograft.
ROS-induced heat shock proteins on damaged cells (or
other molecules arising during injury) in terms of putative
endogenous ligands may activate intragraft donor-derived
and recipient-derived dendritic cells via activation of Toll-
like receptors on their cell surface. This assumption can be
tentatively raised under the aspect that signalling pathways
166 Eur Surg Res 2002;34:160–169 Land
known to occur after TLR-activation (NF-ÎB/Toll-like
receptor pathway), leading to events of inflammation [20,
28], are induced by ROS as well. Indeed, signalling path-
ways downstream Toll-like receptors have remarkable sim-
ilarities with ROS-induced signalling pathways.
Thus, considerable evidence has accumulated support-
ing a role for ROS as activators of signalling pathways and
transcription factors such as NFÎB [34–36] and AP-1 [37]
known to regulate and control acute inflammatory and
immune events via activation of early response genes.
Recent knowledge suggests that extracellular ROS may
affect specific redox-sensitive signalling proteins at or
near the cell membrane which will then initiate signalling
pathways, whereas intracellular ROS may operate and act
as second messengers for a variety of other signalling pro-
cesses of the same type [38, 39]. Once donor-derived and
recipient-derived antigen-presenting dendritic cells are
activated and mature, they are supposed to interact with
recipient’s T-cells and – as a linking bridge – to induce,
initiate and propagate the recipient’s adaptive alloim-
mune response via subsequent events of alloactivation.
As already discussed by us [4, 5], postischemic reperfu-
sion injury to an allograft has been shown to upregulate
the expression of molecules on all three molecular levels
of the dendritic cell surface involved in the interaction
with a T-cell that leads to its activation: MHC class I and
II molecules, costimulatory molecules, and adhesion mol-
ecules.
Altogether, the primary unspecific injury to the foreign
donor organ induces events of the two immunological
defence systems: (1) a more broadly-directed innate im-
mune host defence (evolutionary normally directed
against infection) resulting in (2) a definite adaptive
immune host defence that leads ultimately to a specific
injury to the allograft.
Avoidance of Reperfusion Injury to an
Allograft: An Absolute Requirement for
Successful Induction of Allotolerance?
We speculated already earlier that successful induction
of allotolerance is impossible as long as allografts are
injured during the first minutes of reperfusion after im-
plantation in the recipient. These assumptions were based
on early suggestions that professional antigen-presenting
cells that react with naive T-cells only by signal 1 and not
by signal 2 or costimulatory signal (elicited by a danger
signal) induce and maintain an unresponsive state of tol-
erance [40]. Postischemic reperfusion injury to an allo-
graft, however, via establishment of an inflammatory
milieu, contributes to activation and maturation of intra-
graft dendritic cells and, thus, to upregulation of costimu-
latory molecule expression providing signal 2: the result is
robust T-cell alloactivation, clonal expansion and alloim-
munity [5].
Avoidance of postischemic reperfusion injury would
imply a priori absence of an inflammatory state of the
allograft and, thus, uptake and presentation of allogeneic
antigens would be provided by immature and non-acti-
vated intragraft dendritic cells (e.g. by absence of an inter-
action between endogenous ligands on damaged cells with
Toll-like receptors of DCs). These APCs, then, fail to sup-
port robust T-cell activation, proliferation, and survival
of naive T-cells, and instead tend to induce clonal anergy
and deletion of T-cells.
In addition, recent data suggest a role of apoptotic pro-
cesses not only in the induction but also in the mainte-
nance of tolerance by favouring the development of an
active immunoregulatory state [41].
Anergic and apoptotic T cells generated during the pro-
cess of tolerance induction actively oppose and inhibit
further APCs maturation/activation, which reinforces the
tolerant state. Therefore, the induction of apoptotic T-cell
deletion and anergy by immature dendritic cells may
represent a negative feedback loop, perpetuating a toler-
ant state by opposing the maturation of new dendritic cell
precursors [41–49]. This scenario is illustrated in fig-
ure 4a, b.
Outlook
The concept of ‘innate alloimmunity’ has to be fol-
lowed and investigated further, not only on behalf of the
reperfused allograft in the recipient but also on behalf of
the brain-dead donor. Research should include a search
for the generation of reactive oxygen species, expression
of heat shock proteins on donor cells and of Toll-like
receptors on dendritic cells.
In case of confirmation of the concept, which may con-
tinue to gain credence, future targets of immunosuppres-
sion should then include methods to prevent injury to the
donor organ and its consequences, e.g. by using antioxi-
dants. In addition, such strategies to suppress events dur-
ing innate immunity rather than events during adaptive
immunity should include attempts to develop monoclo-
nal antibodies against Toll-like receptors and/or heat
shock proteins, etc.
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Fig. 4. a Postischemic reperfusion injury and modulation of dendritic cell maturation and activation: the role of
apoptotic T-cells (figure modified according to ref. 41): Presence of reperfusion injury leads to activation of dendritic
cells resulting – via a stimulatory loop – in rejection. b Postischemic reperfusion injury and modulation of dendritic
cell maturation and activation: the role of apoptotic T-cells (figure modified according to ref. 41). Absence of reperfu-
sion injury does not lead to activation of dendritic cells resulting – via the regulatory feed-back loop – in T-cell
apoptosis and tolerance induction.
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